2026年
1. Protective Effects of Imeglimin Against Oxaliplatin-Induced Peripheral
Neurotoxicity: Evidence From In Vitro and In Vivo Studies.
Koura Y, Kinjo K, Mine K, Mori Y, Ueda M, Kaneko R, Kamiya Y, Sonoda T,
Mimata H, Fujita S, Kawashiri T, Kobayashi D.
J Appl Toxicol. 2026.
2. Concomitant Use of DPP-4 Inhibitors May Prevent the Development of Oxaliplatin-Induced
Peripheral Neuropathy: A Retrospective Cohort Study.
Koura Y, Mine K, Fujita S, Kawashiri T, Mori Y, Ueda M, Kaneko R, Hirota
T, Uchida M, Kobayashi D.
Clin Transl Sci.2026;19(2):e70500.
3. Impact of sodium-glucose cotransporter 2 (SGLT2) inhibitors on hematologic
malignancy risk: Insights from Japanese claims data.
Kawashiri T, Yamamoto N, Fujiwara M, Shimizu T, Kobayashi D, Fujita S,
Shibata N, Hirota T, Uchida M.
J Natl Cancer Inst. 2026.
4. お薬手帳を活用した骨粗鬆症治療薬の服薬継続率向上を目指した取り組みの有効性に関する調査－福岡 Bone アーバンモデル
野口 時恵、林田 諭、汐待 加織、古賀 友一郎、國武 さくら、小林 大介、猪阪 日向子、川尻 雄大、島添 隆雄、木原 太郎
日本薬剤師会雑誌. 2026;78(2):147-154.
2025年
1. Proton pump inhibitor concomitant use to prevent oxaliplatin-induced
peripheral neuropathy: clinical retrospective cohort study.
Mine K, Kawashiri T, Mori K, Mori Y, Ishida H, Kudamatsu H, Fujita S, Uchida
M, Yamada T, Egashira N, Ieiri I, Koyanagi S, Ohdo S, Shimazoe T, Kobayashi
D.
Pharmacotherapy.2025;45(7):435-447.
2. Possible prevention of paclitaxel-induced peripheral neuropathy by concomitant
use of α1-receptor antagonist based on a retrospective study.
Mori K, Kawashiri T, Mine K, Ishida H, Mori Y, Ueda M, Koura Y, Fujita
S, Tsuruta A, Egashira N, Ieiri I, Koyanagi S, Shimazoe T, Kobayashi D.
Support Care Cancer. 2025;33(4):316.
3. Paclitaxel-induced peripheral neuropathy in male rats attenuated by
calmangafodipir, a superoxide dismutase mimetic.
Kawashiri T, Mori K, Ishida H, Ueda M, Yao K, Nagahama F, Mine K, Mori
Y, Koura Y, Fujita S, Shimazoe T, Kobayashi D.
J Pharmacol Sci.2025;157(1):8-11.
4. Response to Comment on "Proton Pump Inhibitor Concomitant Use to
Prevent Oxaliplatin-Induced Peripheral Neuropathy: Clinical Retrospective
Cohort Study".
Mine K, Kawashiri T, Mori Y, Fujita S, Uchida M, Yamada T, Egashira N,
Ieiri I, Koyanagi S, Ohdo S, Shimazoe T, Kobayashi D.
Pharmacotherapy.2025;45(9):623-624.
5. Nationwide Survey of Pharmacist Involvement in Managing Cancer Pain
in Children.
Morio K, Iwai C, Yasuda S, Kawashiri T, Hidaka N, Suzuki A, Uchida M, Takase
H.
J Nippon Med Sch.2025;92(4):337-348.
6. Effectiveness of Statins for Oxaliplatin-Induced Peripheral Neuropathy:
A Multicenter Retrospective Observational Study.
Takechi K, Kawashiri T, Mine K, Ushio S, Hamano H, Hida N, Momo K, Uchiyama
M, Uchida M, Tanaka M, Hidaka N, Yasui H, Ueda M, Fujii R, Hashimoto M,
Sakamoto Y, Uyama K, Niimura T, Hanai Y, Tsuboya A, Suzuki K, Kamiyama
N, Hagiwara H, Okada N, Zamami Y, Ishizawa K.
Clin Transl Sci.2025;18(10):e70318.
7. Class effects of proton pump inhibitors in preventing oxaliplatin-induced
peripheral neurotoxicity.
Mori Y, Mine K, Kawashiri T, Koura Y, Ueda M, Kaneko R, Fujita S, Tsuruta
A, Koyanagi S, Kobayashi D.
J Pharmacol Sci.2025;159(4):279-282.
8. The Effect of Diabetes Medication on the Scores of the GNRI and CONUT
Nutritional Indices: Cross-Sectional and Longitudinal Retrospective Studies.
Fujita S, Nagata K, Kinjo K, Mimata H, Sonoda T, Mine K, Kawashiri T, Hirota
T, Uchida M, Kobayashi D.
Clin Transl Sci. 2025;18(11):e70423.
2024年
1. Cholecystokinin receptor type A are involved in the circadian rhythm
of the mouse retina.
Yamakawa Y, Tsurudome Y, Tamada M, Tsuchimochi Y, Umeda Y, Yoshida Y, Kobayashi
D, Kawashiri T, Kubota T, Matsunaga N, Shimazoe T.
Heliyon.2024;10(12):e32653.
2. Medical economic effect of pharmaceutical interventions by board-certified
pharmacists in palliative pharmacy for patients with cancer using medical
narcotics in Japan: a multicenter, retrospective study.
Kawashiri T, Sugawara H, Makihara K, Ohno R, Miyamoto Y, Hidaka N, Uchida
M, Takase H.
J Nippon Med Sch. 2024;91(1):59-65.
3. Risk Factor for Rash in Patients Receiving Cytarabine and Idarubicin
Induction Therapy for Acute Myeloid Leukemia.
Uchida M, Ishida S, Mochizuki E, Ozawa N, Yonemitsu H, Ochiai H, Nakamura
H, Kawashiri T, Watanabe H, Tsuji T, Suetsugu K, Kato K, Egashira N, Akashi
K, Ieiri I.
Cancer Diagn Progn.2024;4(5):617-622.
2023年
1. Ameliorating effects of cystine and theanine in a cancer cachexia mouse
model.
Kudamatsu H, Kawashiri T, Mine K, Mori K, Inoue M, Ishida H, Uchida M,
Tsuchiya T, Kobayashi D, Shimazoe T.
J Pharmacol Sci. 2023;152(3):163-166.
2. Medical opioid disposal in Fukuoka and Kumamoto cities.
Ota A, Kurata S, Tatsuma K, Isaka H, Higuchi Y, Nishina T, Haraguchi K,
Takaki J, Kihara T, Tanaka T, Amagata T, Inaba I, Kawashiri T, Kobayashi
D, Shimazoe T.
Yakugaku Zasshi. 2023;143(5):459-464.
3. Usefulness of a medication instruction sheet for patients receiving
cytarabine and idarubicin induction therapy for acute myeloid leukemia.
Uchida M, Mochizuki E, Ishida S, Ozawa N, Yonemitsu H, Ochiai H, Nakamura
H, Kawashiri T, Kato K, Egashira N, Akashi K, Ieiri I.
In Vivo.2023;37(2):924-932.
4. Development of real-world data-based medication instruction sheet for
acute myeloid leukemia patients receiving high-dose cytarabine consolidation
therapy.
Uchida M, Ishida S, Mochizuki E, Ozawa N, Yonemitsu H, Ochiai H, Nakamura
H, Kawashiri T, Kato K, Egashira N, Akashi K, Ieiri I.
Anticancer Res. 2023;43(7):3321-3329.
5. Improvement of medication guidance sheet for total body irradiation/cyclophosphamide
followed by allogeneic hematopoietic stem cell transplantation based on
real monitoring data.
Uchida M, Ishida S, Mochizuki E, Ozawa N, Yonemitsu H, Ochiai H, Nakamura
H, Kawashiri T, Kato K, Egashira N, Akashi K, Ieiri I.
Anticancer Res. 2023;43(9):4067-4075.
2022年
1. Inhibitory effect of α1 receptor antagonists on paclitaxel-induced peripheral
neuropathy in a rodent model and clinical database.
Mori K, Kawashiri T, Mine K, Inoue M, Kudamatsu H, Uchida M, Egashira N,
Kobayashi D, Shimazoe T.
Toxics. 2022;10(11):669.
2. Omeprazole suppresses oxaliplatin-induced peripheral neuropathy in a
rodent model and clinical database.
Mine K, Kawashiri T, Inoue M, Kobayashi D, Mori K, Hiromoto S, Kudamatsu
H, Uchida M, Egashira N, Koyanagi S, Ohdo S, Shimazoe T.
Int J Mol Sci. 2022;23(16):8859.
3. Analysis of the thinking process of pharmacists in response to changes
in the dispensing environment using the eye-tracking method.
Tsuji T, Nagata K, Sasaki K, Matsukane R, Ishida S, Kawashiri T, Suetsugu
K, Watanabe H, Hirota T, Iei